YIH
CTNM

Y-Intercept (HK)’s Contineum Therapeutics CTNM Stock Holding History

Y-Intercept (HK)’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,156
Closed -$140K – 2135
2025
Q2 		$140K Buy
+35,156
New +$153K ﹤0.01% 1506

Other funds holding CTNM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Y-Intercept (HK)'s CTNM Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Contineum Therapeutics (CTNM) in Q3 2025, closing a stake of 35,156 shares — an estimated $140K sold.

Y-Intercept (HK) first reported a position in CTNM in Q2 2025 and held it in 1 quarter. The position peaked at $140K in Q2 2025. 62 funds tracked by Wall St. Rank hold CTNM as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Contineum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 35,156 Contineum Therapeutics shares in Q3 2025, an estimated $140K.
  • Y-Intercept (HK) first reported a position in Contineum Therapeutics in Q2 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Contineum Therapeutics position peaked at $140K in Q2 2025.
  • 62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.